DNA定量分析在非小细胞肺癌化疗中的价值

目的：探讨ＤＮＡ定量分析在非小细胞肺癌化疗中的作用。方法：９０例非小细胞肺癌患者应用ＭＶＣ方案治疗，化疗前采用流式细胞仪测定其细胞ＤＮＡ含量。结果：ＤＮＡ含量为异倍体者４９例，二倍体４１例，高Ｓ期百分比者３１例，低Ｓ期百分比者５９例，比疗总有铲率为４６．７％，其中异倍体肿瘤化疗有效率为５７．１％，二倍体者有效率为３４．１％，两者相比较差异具有显著性（Ｐ〈０．０５）；高Ｓ期百分比者化疗有效率为７４．

Value of DNA quantitative analysis in planning of chemotherapy of non small cell lung cancer

Purpose:To assess the value of DNA quantitative analysis in the planning of chemotherapy of non small cell lung cancer.Methods:90 cases of non small cell lung cancer were analyzed by flow cytometry and treated by MVC regimen. Results:41 tumors were aneupliod and 49 dipliod, 31 tumors with high S phase fraction and 59 low S phase fraction. Overall response rate (RR) was 46.7%, in aneuploid patients, the RR was 57.1%, and in diploid patients it was 34.1%, the RRs in patients with high and low S phase fraction were 74.2% and 32.2% respectively. Comparison showed that aneuploid tumors and tumors with high S phase fraction appeared to respond better to chemotherapy than diploid tumors and tumors with low S phase fraction, the differences were significant ( P <0 05). Conclusions:These findings indicate that non small cell lung cancer with aneuploidy or high S phase fraction is more sensitive to chemotherapy, the pretreatment DNA quantitative analysis may be useful in selecting high risk patients who might benifit from chemotherapy.